[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370652-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-370652-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","comprehensive-pan-cancer-analysis-and-experimental-validation-reveal-fchsd1-as-a-potential-biomarker-for-diagnosis-immune-infiltration-and-prognosis","Comprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune infiltration, and prognosis","","FCHSD1 is analyzed as a pan-cancer biomarker with emphasis on diagnostic value, immune infiltration patterns, and prognostic relevance. Public genomic and expression resources (TIMER, GEPIA, UALCAN, R packages, cBioPortal) are integrated to characterize expression elevation across tumor types, relationships with clinical and molecular features, and associations with patient survival. Immune correlation is assessed using TIMER and TISIDB, while STRING and GeneMANIA support pathway and network interpretation. In vitro validation in renal cancer cells and tissues confirms functional impacts of FCHSD1 knockdown on proliferation and migration, supporting immunotherapeutic targeting potential.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/comprehensive-pan-cancer-analysis-and-experimental-validation-reveal-fchsd1-as-a-potential-biomarker-for-diagnosis-immune-infiltration-and-prognosis/370652/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/comprehensive-pan-cancer-analysis-and-experimental-validation-reveal-fchsd1-as-a-potential-biomarker-for-diagnosis-immune-infiltration-and-prognosis/370652.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is FCHSD1 and why is it studied in this pan-cancer work?","Question",{"text":63,"@type":64},"FCHSD1 is a member of the F-BAR family containing an amino terminal F-BAR domain and two SH3 domains. The study focuses on whether it can predict diagnosis-related features, immune infiltration, and prognosis across cancers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and tools are used to analyze FCHSD1 expression and clinical relevance?",{"text":68,"@type":64},"Expression profiles are evaluated using TIMER, GEPIA, R packages, and UALCAN. Genetic alterations across pan-cancer are assessed via cBioPortal, and prognosis associations are tested using survival analysis from GEPIA and R packages.",{"name":70,"@type":61,"acceptedAnswer":71},"How is immune infiltration linked to FCHSD1 in different cancer types?",{"text":72,"@type":64},"Immune infiltration correlations are examined with TIMER and TISIDB. Higher FCHSD1 expression is reported to be positively correlated with immune cell infiltration across multiple cancer types.",{"name":74,"@type":61,"acceptedAnswer":75},"What experimental validation supports the study’s conclusions?",{"text":76,"@type":64},"In vitro experiments in renal cancer cells and tissues show higher FCHSD1 expression than in normal and adjacent non-cancerous samples. Functional assays indicate that FCHSD1 knockdown significantly suppresses proliferation and migration in ACHN and 769P cells.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},370652,1790218853,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","TYPE Original Research PUBLISHED 04 June 2025  \nDOI 10.3389/fonc.2025.1547067  \nOPEN ACCESS  \nEDITED BY  \nJehad Charo,  \nRoche, Switzerland  \nREVIEWED BY  \nPingping Chen,  \nUniversity of Miami, United States Tang Tao,  \nSun Yat-sen University Cancer Center (SYSUCC), China  \n*CORRESPONDENCE  \nJitao Wu  \n [wjturology@163.com](wjturology@163.com)[ ](wjturology@163.com)Qingsong Zou  \n [zou_qingsong@126.com](zou_qingsong@126.com)  \n†These authors have contributed equally to this work and share ﬁrst authorship  \nRECEIVED 17 December 2024  \nACCEPTED 12 May 2025  \nPUBLISHED 04 June 2025  \nCITATION  \nLiu M, Ding G, Tang G, Liu S, Mao Q, Wang X, Zou Q and Wu J (2025) Comprehensive pancancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune inﬁltration, and prognosis. Front. Oncol. 15:1547067 .  \ndoi: 10.3389/fonc.2025.1547067  \nCOPYRIGHT  \n© 2025 Liu, Ding, Tang, Liu, Mao, Wang, Zou and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nComprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune inﬁltration, and prognosis  \nMing Liu 1,2†, Guixin Ding 2†, Gonglin Tang 2†, Shangjing Liu 2, Qiancheng Mao 2, Xidong Wang 2, Qingsong Zou 2* and Jitao Wu 2*  \n1Second Clinical Medical College, Binzhou Medical University, Yantai, Shandong, China, 2 Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, China  \nBackground: FCHSD1 is a member of the F-BAR family containing one amino terminal F-BAR domain and two SH3 domains. At present, there are no relevant pan-cancer comprehensive studies on the predictive potential and immune inﬁltration of FCHSD1 for cancer.  \nMethods: FCHSD1 expression proﬁles were analyzed through the use of various tools, including TIMER, GEPIA, R packages, and the UALCAN database. The genetic alteration status of FCHSD1 in human pan-cancer was studied using the cBioPortal website. The effect of FCHSD1 on immune inﬁltration was examined using the TIMER and TISIDB databases. We conﬁrmed the association between FCHSD1 expression and patient prognosis using survival analysis from GEPIA and R packages. The drug database was utilized to analyze the sensitivity of FCHSD1 to drugs. The FCHSD1 interactive genes were obtained through the STRING and GeneMANIA platforms, respectively, and analyzed by GO and KEGG. The expression and function of FCHSD1 in renal cancer cells and tissues have also been biologically validated in vitro.  \nResults: FCHSD1 expression was found to be elevated in tumor tissues compared to adjacent tissues. The expression of FCHSD1 varied across different clinical stages, pathological stages, immune types, and molecular subtypes. Higher expression of FCHSD1 predicts worse outcomes for several cancer types, such as CHOL and KIRC. High FCHSD1 expression was positively correlated with immune cell inﬁltration in different cancer types. Additionally, the FCHSD1 coexpression gene network may be involved in endocytosis. In vitro experiments revealed that the expression of FCHSD1 in renal cancer cells and tissues was higher than that in normal cells and adjacent non-cancerous tissues. Functional assays revealed that FCHSD1 knockdown signiﬁcantly suppressed proliferation and migration in ACHN and 769P cells.  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nConclusion: FCHSD1 has the potential to serve as a prognostic and immunological marker for pan-cancer, and may also be a crucial target for future immunotherapy.  \nKEYWORDS  \nFCHSD1, expression proﬁle, prognosis, ","cbCaiv6y4BeKocsY","https://ap.wps.com/l/cbCaiv6y4BeKocsY","pdf",18229152,17,"English","# Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What is FCHSD1 and why is it studied in this pan-cancer work?\",\"answer\":\"FCHSD1 is a member of the F-BAR family containing an amino terminal F-BAR domain and two SH3 domains. The study focuses on whether it can predict diagnosis-related features, immune infiltration, and prognosis across cancers.\"},{\"question\":\"Which datasets and tools are used to analyze FCHSD1 expression and clinical relevance?\",\"answer\":\"Expression profiles are evaluated using TIMER, GEPIA, R packages, and UALCAN. Genetic alterations across pan-cancer are assessed via cBioPortal, and prognosis associations are tested using survival analysis from GEPIA and R packages.\"},{\"question\":\"How is immune infiltration linked to FCHSD1 in different cancer types?\",\"answer\":\"Immune infiltration correlations are examined with TIMER and TISIDB. Higher FCHSD1 expression is reported to be positively correlated with immune cell infiltration across multiple cancer types.\"},{\"question\":\"What experimental validation supports the study’s conclusions?\",\"answer\":\"In vitro experiments in renal cancer cells and tissues show higher FCHSD1 expression than in normal and adjacent non-cancerous samples. Functional assays indicate that FCHSD1 knockdown significantly suppresses proliferation and migration in ACHN and 769P cells.\"}]","Comprehensive pan-cancer analysis and experimental validation reveal FCHSD1 as a potential biomarker for diagnosis, immune infiltration, and prognosis | PDF",1790189654,43,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8650b1b97bc606ccdb10a6464c7e492f.webp",983,1389,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a5e8d3bea9f2c4773558caa336b3bc3.webp",982,1388,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3092b413db7c9ec0d82bf8f5cfa8b902.webp",981,1387,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f07c12058f5f48c58f50327881912c65.webp",980,1385]